Improving platelet transfusion safety: Biomedical and technical considerations

Blood Transfusion

Volumn 14, Issue 2, 2016, Pages 109-122

  Garraud, Olivier ^a,b   Cognasse, Fabrice ^b,c   Tissot, Jean Daniel ^d   Chavarin, Patricia ^c   Laperche, Syria ^a   Morel, Pascal ^e   Lefrère, Jean Jacques ^a,f   Pozzetto, Bruno ^b   Lozano, Miguel ^g   Blumberg, Neil ^h   Osselaer, Jean Claude ^d  

^a INSTITUT NATIONAL DE LA TRANSFUSION SANGUINE   (France)

^b UNIVERSITÉ DE LYON   (France)

^c Auvergne Loire French Blood Establishment   (France)

^d Blood Transfusion Service of the Swiss Red Cross   (Switzerland)

^e French Blood Agency Bourgogne Franche Comté   (France)

^f UNIVERSITÉ PARIS DESCARTES   (France)

^g HOSPITAL CLÍNIC   (Spain)

^h UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Apheresis platelet components; Platelet components; Transfusion; Whole blood platelet components

Indexed keywords

THROMBOCYTE CONCENTRATE;

ALLOIMMUNIZATION; BACTERIUM CONTAMINATION; BLOOD COMPONENT; BLOOD SAFETY; DONOR SELECTION; GOLD STANDARD; HEALTH HAZARD; HEMODILUTION; HUMAN; IMMUNOLOGICAL PROCEDURES; IMMUNOMODULATION; INFECTION; INFECTION RISK; INFLAMMATION; LEUKAPHERESIS; PATIENT SAFETY; PLASMAPHERESIS; PRION; PRION DISEASE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SHELF LIFE; STORAGE TEMPERATURE; THROMBOCYTE; THROMBOCYTE FUNCTION; THROMBOCYTE PRESERVATION; THROMBOCYTE TRANSFUSION; TRANSFUSION ASSOCIATED GRAFT VERSUS HOST DISEASE; VIRUS TRANSMISSION; BLOOD STORAGE; PROCEDURES;

BLOOD PRESERVATION; BLOOD SAFETY; HUMANS; PLATELET TRANSFUSION;

EID: 84961677994     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2015.0042-15     Document Type: Review

References (123)

1. Schmidt M, Geilenkeuser WJ, Sireis W, et al. Emerging pathogens - how safe is blood? Transfus Med Hemother 2014; 41: 10-7.
2. Franklin IM Blood transfusion safety: a new philosophy. Transfus Med 2012; 22: 377-82.
3. Chord-Auger S, Tron de Bouchony E, Moll MC, et al. Satisfaction survey in general hospital personnel involved in blood transfusion: implementation of the ISO9001: 2000 standard. Transfus Clin Biol 2004; 11: 177-82.
4. Dodd RY Emerging pathogens and their implications for the blood supply and transfusion transmitted infections. Br J Haematol 2012; 159: 135-42.
5. Quaranta JF, Berthier E, Courbil R, et al.; Le Groupe Receveurs. Société Française de Transfusion Sanguine. [Who are the recipients of labile blood products? A multicenter nation-wide study - a "donation day." Blood banks, health facilities] Transfus Clin Biol 2009; 16: 21-9. [In French.]
6. ANSM. Rapport d'activité Hémovigilance; 2013. Available at: http://www.ansm.sante.fr/var/ansm-site/storage/original/application/8a2c3c478172fcfbe027742aed130adf.pdf. Accessed on 12/06/2015.
7. Katus MC, Szczepiorkowski ZM, Dumont LJ, Dunbar NM. Safety of platelet transfusion: past, present and future. Vox Sang 2014; 107: 103-13.
8. Karim F, Moiz B, Shamsuddin N, et al. Root cause analysis of non-infectious transfusion complications and the lessons learnt. Transfus Apher Sci 2013; 50: 111-7.
9. The European Blood Alliance (EBA). Blood, Tissues and cells of human origins; 2013. Available at: http://www.europeanbloodalliance.eu/wp-content/uploads/2013/04/eba-online.pdf. Accessed on 12/06/2015.
10. Lafeuillade B, Eb F, Ounnoughene N, et al. Residual risk and retrospective analysis of transfusion-transmitted bacterial infection reported by the French National Hemovigilance Network from 2000 to 2008. Transfusion 2015; 55: 636-46.
11. Morel P, Deschaseaux M, Bertrand X, et al. Maîtrise du risque bactérien transfusionnel en France en 2013. Transfu Clin Biol 2013; 20: 174-81.
12. Goodnough LT, Levy JH, Murphy MF. Concepts of blood transfusion in adults. Lancet 2013; 381: 1845-54.
13. Siblini L, Lafeuillade B, Ros A, et al. Influence of blood prestorage conditions and white blood cell filtration on the bacterial load of blood deliberately inoculated with Grampositive and Gram-negative pathogens. Vox Sang 2004; 87: 241-9.
14. Siblini L, Lafeuillade B, Ros A, et al. Reduction of Yersinia enterocolitica load in deliberately inoculated blood: the effects of blood prestorage temperature and WBC filtration. Transfusion 2002; 42: 422-7.
15. Cid J, Magnano L, Lozano M. Automation of blood component preparation from whole blood collections. Vox Sang 2014; 107: 10-8.
16. Amrein K, Katschnig C, Sipurzynski S, et al. Apheresis affects bone and mineral metabolism. Bone 2010; 46: 789-95.
17. Buchta C, Macher M, Bieglmayer C, et al. Reduction of adverse citrate reactions during autologous large-volume PBPC apheresis by continuous infusion of calcium-gluconate. Transfusion 2003; 43: 1615-21.
18. Ounnoughene N, Sandid I, Carlier M, et al. [The blood donors' haemovigilance in France.] Transfus Clin Biol 2013; 20: 182-92. [In French.]
19. th ed. Strasbourg: Council of Europe Publishing; 2013.
20. st century. Transfusion 2013; 53: 438-54.
21. Francis RO, Strauss D, Williams JD, et al. West Nile virus infection in blood donors in the New York City area during the 2010 seasonal epidemic. Transfusion 2012; 52: 2664-70.
22. Appassakij H, Khuntikij P, Kemapunmanus M, et al. Viremic profiles in asymptomatic and symptomatic chikungunya fever: a blood transfusion threat? Transfusion 2013; 53: 2567-74.
23. Stramer SL, Linnen JM, Carrick JM, et al. Dengue viremia in blood donors identified by RNA and detection of dengue transfusion transmission during the 2007 dengue outbreak in Puerto Rico. Transfusion 2012; 52: 1657-66.
24. Rasonglès P, Angelini-Tibert MF, Simon P, et al. Transfusion of platelet components prepared with photochemical pathogen inactivation treatment during a Chikungunya virus epidemic in Ile de La Réunion. Transfusion 2009; 49: 1083-91.
25. Garraud O, Lefrère JJ. Voluntary non-remunerated blood donation and reasons for donating: is there room enough for philosophy? Blood Transfus 2014; S1: s404-5.
26. Hauser L, Beyloune A, Simonet M, Bierling P. [Blood donor hemovigilance: impact for donor and recipient safety]. Transfus Clin Biol 2013; 20: 99-103. [In French.]
27. Bode AP, Fischer TH. Lyophilized platelets: fifty years in the making. Artif Cells Blood Substit Immobil Biotechnol 2007; 35: 125-33.
28. Reade MC, Marks DC, Johnson L, et al. Frozen platelets for rural Australia: the CLIP trial. Anaesth Intensive Care 2013; 41: 804-5.
29. Vamvakas EC The abandoned controversy surrounding universal white blood cell reduction. Blood Transfus 2014; 12: 143-5.
30. Vamvakas EC, Blajchman MA. Transfusion-related immunomodulation (TRIM): an update. Blood Rev 2007; 21: 327-48.
31. Bilgin YM, van de Watering LM, Brand A. Clinical effects of leucoreduction of blood transfusions. Neth J Med 2011; 69: 441-50.
32. Lannan KL, Sahler J, Spinelli SL, et al. Transfusion immunomodulation - the case for leukoreduced and (perhaps) washed transfusions. Blood Cells Mol Dis 2013; 50: 61-8.
33. Donati A, Damiani E, Luchetti M, et al. Microcirculatory effects of the transfusion of leukodepleted or non-leukodepleted red blood cells in patients with sepsis: a pilot study. Crit Care 2014; 18: R33.
34. Garraud O, Chabert A, Pozzetto B, et al. Non leuko-depleted red cell transfusion in sepsis patents: beyond oxygenation, is there a risk of inflammation? Crit Care 2014; 18: 690.
35. Pavenski K, Freedman J, Semple JW. HLA alloimmunization against platelet transfusions: pathophysiology, significance, prevention and management. Tissue Antigens 2012; 79: 237-45.
36. Garraud O, Hamzeh-Cognasse H, Pozzetto B, et al. Bench-to-bedside review: Platelets and active immune functions - new clues for immunopathology? Crit Care 2013; 17: 236.
37. Delbosc A, Lafeuillade B, Petermann R, et al. [Transfusion-transmitted bacterial infectious (TTBI) with blood component accountability score 2: Retrospective analysis of the French e-fit database 2000-2007. Groupe de travail - validation des IBTT (Working group for validation of transfusion-transmitted bacterial infections).] Transfus Clin Biol 2011; 18: 26-35. [In French.]
38. Benjamin RJ, McDonald CP; ISBT Transfusion Transmitted Infectious Disease Bacterial Workgroup. The international experience of bacterial screen testing of platelet components with an automated microbial detection system: a need for consensus testing and reporting guidelines. Transfus Med Rev 2014; 28: 61-71.
39. Störmer M, Vollmer T. Diagnostic methods for platelet bacteria screening: current status and developments. Transfus Med Hemother 2014; 41: 19-27.
40. Heaton WA, Good CE, Galloway-Haskins R, et al. Evaluation of a rapid colorimetric assay for detection of bacterial contamination in apheresis and pooled random-donor platelet units. Transfusion 2014; 54: 1634-41.
41. Pietersz RN, Reesink HW, Panzer S, et al. Bacterial contamination in platelet concentrates. Vox Sang 2014; 106: 256-83.
42. European Commission. Health and Consumer Protection Directorate-General. Opinion on quality and safety of blood adopted by the Scientific Committee on Medical Products and Medical Devices on 16 February 2000. Available at: http://ec.europa.eu/health/archive/ph-risk/committees/scmp/documents/out29-en.pdf. Accessed on 12/06/2015.
43. El Ichi S, Leon F, Vossier L, et al. Microconductometric immunosensor for label-free and sensitive detection of Gramnegative bacteria. Biosens Bioelectron 2014; 54: 378-84.
44. Webert KE, Cserti CM, Hannon J, et al. Proceedings of a Consensus Conference: pathogen inactivation-making decisions about new technologies. Transfus Med Rev 2008; 22: 1-34.
45. Council of Europe. European Directorate for the Quality of Medicines & HealthCare. Symposium on Implementation of Pathogen Reduction Technologies for Blood Components. Executive Summary. Strasbourg, 2-3 September 2010.
46. Hechler B, Ohlmann P, Chafey P, et al. Preserved functional and biochemical characteristics of platelet components prepared with amotosalen and ultraviolet A for pathogen inactivation. Transfusion 2013; 53: 1187-200.
47. Jimenez-Marco T, Fisa R, Riera C, et al. Pathogen inactivation technology applied to a blood component collected from an asymptomatic carrier of Leishmania infantum: a case report. Vox Sang 2012; 103: 356-8.
48. Kaiser-Guignard J, Canellini G, Lion N, et al. The clinical and biological impact of new pathogen inactivation technologies on platelet concentrates. Blood Rev 2014; 28: 235-44.
49. Schlenke P. Pathogen inactivation technologies for cellular blood components: an update. Transfus Med Hemother 2014; 41: 309-25.
50. Hauser L, Roque-Afonso AM, Beylouné A, et al. Hepatitis E transmission by transfusion of Intercept blood system-treated plasma. Blood 2014; 123: 796-7.
51. Vamvakas EC Meta-analysis of the studies of bleeding complications of platelets pathogen-reduced with the Intercept system. Vox Sang 2012; 102: 302-16.
52. Lai C, Cao H, Hearst JE, et al. Quantitative analysis of DNA interstrand cross-links and monoadducts formed in human cells induced by psoralens and UVA irradiation. Anal Chem 2008; 80: 8790-8.
53. Vetlesen A, Mirlashari MR, Akkök CA, et al. Biological response modifiers in photochemically pathogen-reduced versus untreated apheresis platelet concentrates. Transfusion 2013; 53: 147-55.
54. Cognasse F, Osselaer JC, Payrat JM, et al. Release of immune modulation factors from platelet concentrates during storage after photochemical pathogen inactivation treatment. Transfusion 2008; 48: 809-13.
55. Hamzeh-Cognasse H, Laradi S, Osselaer JC, et al. Amotosalen-HCl-UVA pathogen reduction does not alter poststorage metabolism of soluble CD40 ligand, Ox40 ligand and interkeukin-27, the cytokines that generally associate with serious adverse events. Vox Sang 2015; 108: 205-7.
56. Apelseth TØ, Bruserud Ø, Wentzel-Larsen T, et al. In vitro evaluation of metabolic changes and residual platelet responsiveness in photochemical treated and gamma-irradiated single-donor platelet concentrates during long-term storage. Transfusion 2007; 47: 653-65.
57. Brandel JP, Peckeu L, Haïk S. The French surveillance network of Creutzfeldt-Jakob disease. Epidemiological data in France and worldwide. Transfus Clin Biol 2013; 20: 395-7.
58. Diack AB, Head MW, McCutcheon S, et al. Variant CJD: 18 years of research and surveillance. Prion 2014; 8: pii: 29237.
59. ∗ in human brain. BMC Neurol 2013; 13: 126.
60. Miodek A, Castillo G, Hianik T, Korri-Youssoufi H. Electrochemical aptasensor of cellular prion protein based on modified polypyrrole with redox dendrimers. Biosens Bioelectron 2014; 56: 104-11.
61. Lacroux C, Bougard D, Litaise C, et al. Impact of leucocyte depletion and prion reduction filters on TSE blood borne transmission. PLoS One 2012; 7: e42019.
62. Valeri CR, Ragno G. An approach to prevent the severe adverse events associated with transfusion of FDA-approved blood products. Transfus Apher Sci 2010; 42: 223-33.
63. De Clippel D, Baeten M, Torfs A, et al. Screening for HLA antibodies in plateletpheresis donors with a history of transfusion or pregnancy. Transfusion 2014; 54: 3036-42.
64. Sigle JP, Thierbach J, Infanti L, et al. Anti-leucocyte antibodies in platelet apheresis donors with and without prior immunizing events: implications for TRALI prevention. Vox Sang 2013; 105: 244-52.
65. Blatyta PF, Custer B, Liu J, et al.; NHLBI Retrovirus Epidemiology Donor Study-II (REDSII), International Component. The impact of policies to restrict the use of plasma containing products and apheresis platelets from female donors to mitigate transfusion related acute lung injury (TRALI) in Brazil. Transfus Apher Sci 2013; 48: 15-20.
66. Gajic O, Yilmaz M, Iscimen R, et al. Transfusion from male-only versus female donors in critically ill recipients of high plasma volume components. Crit Care Med 2007; 35: 1645-8.
67. Capocelli KE, Dumont LJ. Novel platelet storage conditions: additive solutions, gas, and cold. Curr Opin Hematol 2014; 21: 491-6.
68. Alhumaidan H, Sweeney J. Current status of additive solutions for platelets. J Clin Apher 2012; 27: 93-8.
69. Dumont LJ, Cancelas JA, Graminske S, et al. In vitro and in vivo quality of leukoreduced apheresis platelets stored in a new platelet additive solution. Transfusion 2013; 53: 972-80.
70. Nguyen KA, Chavarin P, Arthaud CA, et al. Do manual and automated processes with distinct additive solutions affect whole blood-derived platelet components differently? Blood Transfus 2013; 11: 152-3.
71. van de Watering LM. Age of blood: does older blood yield poorer outcomes? Curr Opin Hematol 2013; 20: 526-32.
72. van der Meer PF. Adverse effects of 'old' versus 'young' blood: also true for platelet concentrates? Clin Lab 2011; 57: 260-2.
73. Cognasse F, Boussoulade F, Chavarin P, et al. Release of potential immunomodulatory factors during platelet storage. Transfusion 2006; 46: 1184-9.
74. Cognasse F, Hamzeh-Cognasse H, Lafarge S, et al. Donor platelets stored for at least 3 days can elicit activation marker expression by the recipient's blood mononuclear cells: an in vitro study. Transfusion 2009; 49: 91-8.
75. Cognasse F, Payrat JM, Corash L, et al. Platelet components associated with acute transfusion reactions: the role of platelet-derived soluble CD40 ligand. Blood 2008; 11 2: 4779-80.
76. Hamzeh-Cognasse H, Damien P, Nguyen KA, et al. Immune-reactive soluble OX40 ligand, soluble CD40 ligand, and interleukin-27 are simultaneously oversecreted in platelet components associated with acute transfusion reactions. Transfusion 2014; 54: 613-25.
77. Hamzeh-Cognasse H, Damien P, Nguyen KA, et al. Contribution of activated platelets to plasma IL-27 levels. Crit Care 2013; 17: 411.
78. Sahler J, Spinelli S, Phipps R, Blumberg N. CD40 ligand (CD154) involvement in platelet transfusion reactions. Transfus Clin Biol 2012; 19: 98-103.
79. Nguyen KA, Hamzeh-Cognasse H, Sebban M, et al. A computerized prediction model of hazardous inflammatory platelet transfusion outcomes. PLoS One 2014; 9: e97082.
80. Tanaka S, Hayashi T, Tani Y, Hirayama F. Removal of biological response modifiers associated with platelet transfusion reactions by columns containing adsorption beads. Transfusion 2014; 54: 1790-7.
81. Garraud O, Cognasse F, Hamzeh-Cognasse H, et al. Removal of biological response modifiers associated with platelet transfusion reactions: strategies worth considering? Transfusion 2014; 54: 2583.
82. Sandgren P, Meinke S, Eckert E, et al. Random aggregates in newly produced platelet units are associated with platelet activation and release of the immunomodulatory factors sCD40L and RANTES. Transfusion 2014; 54: 602-12.
83. Nguyen KA, Cognasse C, Boussoulade F, et al. [Platelet components in Blood Transfusion: processing, norm and quality assurance principles to ensure tolerance and safety.] Hématologie 2013; 19: 371-82. [In French.]
84. Garraud O, Cognasse F. Platelet Toll-like receptor expression: the link between "danger" ligands and inflammation. Inflamm Allergy Drug Targets 2010; 9: 322-33.
85. Semple JW, Italiano JE Jr, Freedman J. Platelets and the immune continuum. Nat Rev Immunol 2011; 11: 264-74.
86. Garraud O, Hamzeh-Cognasse H, Laradi S, Cognasse F. Paths to understand and to limit inflammation in transfusion. Eur J Inflamm 2014; 12: 191-5.
87. Aloui C, Sut C, Prigent A, et al. Are polymorphisms of the immunoregulatory factor CD40LG implicated in acute transfusion reactions? Sci Rep 2014; 4: 7239.
88. Andreu G, Vasse J, Sandid I, Semana G. Use of random versus apheresis platelet concentrates. Transfus Clin Biol 2007; 14: 514-21.
89. Willaert B, Vo Mai MP, Caldani C. French hemovigilance data on platelet transfusion. Transfus Med Hemother 2008; 35: 118-21.
90. Rebibo D, Simonet M, Hauser L. [Introduction of platelet additive solution in platelet concentrates: towards a decrease of blood transfusion reactions.] Transfus Clin Biol 2008; 15: 289-93. [In French.]
91. Andreu G, Vasse J, Tardivel R, Semana G. [Platelet transfusion: products, indications, dose, threshold and efficacy.] Transfus Clin Biol 2009; 16: 118-33. [In French.]
92. Marrocco C, D'Alessandro A, Girelli G, Zolla L. Proteomic analysis of platelets treated with gamma irradiation versus a commercial photochemical pathogen reduction technology. Transfusion 2013; 53: 1808-20.
93. rd, et al. White blood cell inactivation after treatment with riboflavin and ultraviolet light. Transfusion 2010; 50: 2489-98.
94. Asano H, Lee CY, Fox-Talbot K, et al. Treatment with riboflavin and ultraviolet light prevents alloimmunization to platelet transfusions and cardiac transplants. Transplantation 2007; 84: 1174-82.
95. Thiele T, Sablewski A, Iuga C, et al. Profiling alterations in platelets induced by Amotosalen/UVA pathogen reduction and gamma irradiation - a LC-ESI-MS/MS-based proteomics approach. Blood Transfus 2012; 10 (Suppl. 2): s63-70.
96. Meyer E, Delaney M, Lin Y, et al. A reporting guideline for clinical platelet transfusion studies from the BEST Collaborative. Transfusion 2013; 53: 1328-34.
97. Cid J, Harm SK, Yazer MH. Platelet transfusion - the art and science of compromise. Transfus Med Hemother 2013; 40: 160-71.
98. Thiagarajan P, Afshar-Kharghan V. Platelet transfusion therapy. Hematol Oncol Clin North Am 2013; 27: 629-43.
99. Bercovitz RS, Kelher MR, Khan SY, et al. The pro-inflammatory effects of platelet contamination in plasma and mitigation strategies for avoidance. Vox Sang 2012; 102: 345-53.
100. Sahler J, Grimshaw K, Spinelli SL, et al. Platelet storage and transfusions: new concerns associated with an old therapy. Drug Discov Today Dis Mech 2011; 8: e9-14.
101. Heddle NM, Fung M, Hervig T, et al.; BEST Collaborative. Challenges and opportunities to prevent transfusion errors: a Qualitative Evaluation for Safer Transfusion (QUEST). Transfusion 2012; 52: 1687-95.
102. Dunbar NM, Ornstein DL, Dumont LJ. ABO incompatible platelets: risks versus benefit. Curr Opin Hematol 2012; 19: 475-9.
103. Lozano M, Cid J. The clinical implications of platelet transfusions associated with ABO or Rh(D) incompatibility. Transfus Med Rev 2003; 17: 57-68.
104. Rioux-Massé B, Cohn C, Lindgren B, et al. Utilization of cross-matched or HLA-matched platelets for patients refractory to platelet transfusion. Transfusion 2014; 54: 3080-7.
105. Lozano M, Mahon A, van der Meer PF, et al; Biomedical Excellence for Safer Transfusion (BEST) Collaborative. Counting platelets at transfusion threshold levels: impact on the decision to transfuse. A BEST Collaborative - UK NEQAS(H) International Exercise. Vox Sang 2014; 106: 330-6.
106. Wandt H, Schaefer-Eckard K, Wendelin K, et al.; Study Alliance Leukemia. Therapeutic platelet transfusion versus routine prophylactic transfusions in patients with haematologic malignancies: an open-label, multicentre, randomized study. Lancet 2013; 380: 1309-16.
107. Slichter SJ, Kaufman RM, Assmann SF, et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. N Engl J Med 2010; 362: 600-13.
108. Slichter SJ New thoughts on the correct dosing of prophylactic platelet transfusion to prevent bleeding. Curr Opin Hematol 2011; 18: 427-35.
109. Kaufman RM, Djulbegovic B, Gernsheimer T, et al.; AABB. Platelet transfusion: a clinical practice guideline from the AABB. Ann Intern Med 2015; 162: 205-13.
110. Corash L, Sherman CD. Evaluation of platelet transfusion clinical trials. Br J Haematol 2011; 153: 529-31.
111. Kerkhoffs JL, van Putten WL, Novotny VM, et al.; Dutch-Belgian HOVON cooperative group. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. Br J Haematol 2010; 150: 209-17.
112. Ypma PF, Kerkhoffs JL, van Hilten JA, et al. The observation of bleeding complications in haemato-oncological patients: stringent watching, relevant reporting. Transfus Med 2012; 22: 426-31.
113. Estcourt LJ, Heddle N, Kaufman R, et al.; Biomedical Excellence for Safer Transfusion Collaborative. The challenges of measuring bleeding outcomes in clinical trials of platelet transfusions. Transfusion 2013; 53: 1531-43.
114. Wood L, Jogessar V, Ward P, Jacobs P. Estimation and predictive use of the corrected count increment - a proposed clinical guideline. Transfus Apher Sci 2005; 32: 117-24.
115. Refaai MA, Phipps RP, Spinelli SL, Blumberg N. Platelet transfusions: impact on hemostasis, thrombosis, inflammation and clinical outcomes. Thromb Res 2011; 127: 287-91.
116. Levin E, Jenkins C, Culibrk B, et al. Development of a quality monitoring program for platelet components: a report of the first four years' experience at Canadian Blood Services. Transfusion 2012; 52: 810-8.
117. th List, Apr. 2013; final amendments, Oct. 2013). Available at: http://apps.who.int/iris/bitstream/10665/93142/1/EML-18-eng.pdf?ua=1. Accessed on 12/06/2015.
118. Lee CK, Wong HK, Ho PL, et al. Significant bacterial contamination risk reduction with the use of diversion pouch. Transfus Med 2012; 22: 404-8.
119. Kitchen AD, Chiodini PL, Tossell J. Detection of malarial DNA in blood donors-evidence of persistent infection. Vox Sang 2014; 107: 123-31.
120. Sonnleitner ST, Fritz J, Bednarska M, et al. Risk assessment of transfusion-associated babesiosis in Tyrol: appraisal by seroepidemiology and polymerase chain reaction. Transfusion 2014; 54: 1725-32.
121. Grigorenko E, Fisher C, Patel S, et al. Multiplex screening for blood-borne viral, bacterial, and protozoan parasites using an OpenArray platform. J Mol Diagn 2014; 16: 136-44.
122. Benjamin RJ, Stramer SL, Leiby DA, et al. Trypanosoma cruzi infection in North America and Spain: evidence in support of transfusion transmission. Transfusion 2012; 52: 1913-21.
123. Takizawa K, Nakashima T, Mizukami T, et al. Degenerate polymerase chain reaction strategy with DNA microarray for detection of multiple and various subtypes of virus during blood screening. Transfusion 2013; 53: 2545-55.